



## COMPANY OVERVIEW

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

## RECENT NEWS

**Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting**  
Dec 11 2025, 5:00 PM EST

**Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform**  
Nov 19 2025, 8:45 AM EST

## STOCK OVERVIEW

Symbol	XBIO
Exchange	Nasdaq
Market Cap	4.9m
Last Price	\$2.14
52-Week Range	\$1.90 - \$13.93

02/11/2026 08:59 PM EST

## INVESTOR RELATIONS

JTC Team, LLC.  
Jenene Thomas  
T: 908-824-0775  
[xbio@jtcir.com](mailto:xbio@jtcir.com)

## MANAGEMENT TEAM

**James F. Parslow**  
Interim Chief Executive Officer and Chief Financial Officer

**Scott N. Cullison**  
Business Development

**Reid P. Bissonnette, Ph.D.**  
Translational Research and Development

## XENETIC BIOSCIENCES, INC.

945 Concord Street  
Framingham, MA 01701  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.